---
title: Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
nct_id: NCT05083299
overall_status: COMPLETED
sponsor: Daewoong Pharmaceutical Co. LTD.
study_type: OBSERVATIONAL
primary_condition: Chronic Occlusive Arterial Disease
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05083299.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05083299"
ct_last_update_post_date: 2024-07-03
last_seen_at: "2026-05-12T06:36:59.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate

**Official Title:** Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate on Symptom Improvement in Patients With Peripheral Arterial Disease

**NCT ID:** [NCT05083299](https://clinicaltrials.gov/study/NCT05083299)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1003
- **Lead Sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Conditions:** Chronic Occlusive Arterial Disease
- **Start Date:** 2020-01-28
- **Completion Date:** 2022-01-20
- **CT.gov Last Update:** 2024-07-03

## Brief Summary

The study will evaluate the effect of Anpl-one SR Tablet on the improvement of symptoms in daily care environments using PAQ.

## Detailed Description

The purpose of this study is to evaluate the effect of Anple-one SR Tablet on the improvement of symptoms in daily care environments within the scope of 300 milligrams of Anpl-one SR Tablet (sarpogrelate hydrochloride agent) using PAQ.

## Eligibility

- **Minimum age:** 19 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

```
Inclusion Criteria:

1. Adults over 19 and under 80 years of age.
2. Patients who first administered Sarpogrelate hydrochloride drugs or less than 3 months to improve ischemic symptoms such as ulcers, pain, and coldness caused by chronic arterial obstruction (Burger's disease, obstructive arteriosclerosis, diabetic peripheral angiopathy, etc.).
3. Patient who voluntarily signed a written consent form approved by the Clinical Trial Review Committee or Ethics Committee and agreed to participate in the study by the patient or the subject's agent.

Exclusion Criteria:

1. Patient who is expected to have less than two years of life expectancy.
2. Patient who have bleeding within a week of participation in the study
3. Patient suffering from diseases that may increase bleeding during study participation (hemophilia, capillary placebo, digestive tube ulcer, urinary tract bleeding, hemoptysis, hyperself-bleeding, etc.).
4. A female patient who is likely to be pregnant or pregnant.
5. Female patients who are lactating or are scheduled to be lactated at the time of participation in the study.
6. Patients with severe renal disease and liver disease.
```

## Arms

- **Anpl-one SR Tablet** — Patients who prescribed Anpl-one SR Tablet

## Interventions

- **Sarpogrelate** (DRUG) — Anpl-one SR

## Primary Outcomes

- **Change in Peripheral Artery Questionnaire** _(time frame: 24 weeks)_ — Change in Peripheral Artery Questionnaire at 24 weeks compared to baseline

## Secondary Outcomes

- **Peripheral Artery Questionnaire change** _(time frame: 12 weeks)_
- **Peripheral Artery Questionnaire change** _(time frame: 24 weeks)_
- **Change in each domain of Peripheral Artery Questionnaire** _(time frame: 24 weeks)_
- **Confirm the relationship between the ABI criteria and PAQ related to the diagnosis of PAD patients** _(time frame: 12 weeks)_
- **Confirm the relationship between the ABI criteria and PAQ related to the diagnosis of PAD patients** _(time frame: 24 weeks)_

## Locations (1)

- BuKyung Kim, Busan, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.bukyung kim|busan||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05083299.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05083299*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*